Vesnarinone: A differentiation-inducing anti-cancer drug

Anti-Cancer Drugs

Volumn 14, Issue 6, 2003, Pages 391-395

  Kawamata, Hitoshi ^a,b   Omotehara, Fumie ^a   Nakashiro, Koh Ichi ^b   Uchida, Daisuke ^c   Hino, Satoshi ^b   Fujimori, Takahiro ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

^b EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Differentiation therapy; p21waf1; TSC 22; Tumor dormancy therapy; Vesnarinone

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOTOXIC AGENT; GEMCITABINE; PIPERANOMETOZINE;

ADVANCED CANCER; APOPTOSIS; BLADDER CANCER; BREAST CANCER; CANCER; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL TRIAL; DRUG ACTIVITY; DRUG POTENTIATION; DRUG TARGETING; HUMAN; LEUKEMIA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; HUMANS; MICE; NEOPLASMS; QUINOLINES; REPRESSOR PROTEINS;

EID: 0042627861     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200307000-00001     Document Type: Review

References (56)

1. Uhr JW, Scheuermann RH, Street NE, Vitetta ES. Cancer dormancy: opportunities for new therapeutic approaches. Nat Med 1997; 3:505-509.
2. Huang M, Ye Y, Chen S, Chai J, Lu J-X, Zhoa L, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72:567-572.
3. Castaigne S, Chomienne C, Daniel MT, Ballerini P, Berger R, Fenaux P, et al. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood 1990; 76:1704-1709.
4. Warrell RP, Frankel SR, Miller WH, Scheinberg DA, Itri LM, Hittelman WN, et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Eng J Med 1991; 324:1385-1393.
5. Kawamata H, Nakashiro K, Uchida D, Hino S, Omotehara F, Yoshida H, et al. Induction of TSC-22 by treatment with a new anti-cancer drug, vesnarinone, in a human salivary cancer cell. Br J Cancer 1998; 77:71-78.
6. Nakashiro K, Kawamata H, Hino S, Uchida D, Miwa Y, Hamano H, et al. Down-regulation of TSC-22 (transforming growth factor β-stimulated clone 22) markedly enhances the growth of a human salivary gland cancer cell line in vitro and in vivo. Cancer Res 1998; 58:549-555.
7. Y antigen expression by Vesnarinone in salivary gland cancer. Proc Am Ass Cancer Res 1995; 36:637.
8. Asanoi H, Sasayama S, Iuchi K, Kameyama T. Acute hemodynamic effects of a new inotropic agent (OPC-8212) in patients with congestive heart failure. J Am Coll Cardio 1987; 9:865-871.
9. Feldman AM, Bristow MR, Parmley WW, Carson PE, Pepine CJ, Gilbert EM, et al. Effects of vesnarinone of morbidity and mortality in patients with heart failure. N Eng J Med 1993; 329:149-155.
10. Cohn JN, Goldstein SO, Greenberg BH, Lorell BH, Bourge RC, Jaski BE, et al. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators. N Eng J Med 1998; 339:1810-1816.
11. Manna SK, Aggarwal BB. Vesnarinone suppreses TNF-induced activation of NF-κB, c-jun kinase, and apoptosis. J Immunol 2000; 164:5815-5825.
12. Sasayama S, Matsumori A, Matoba Y, Matsui T, Yamada T, Shioi Y, et al. Immunomodulation: a new horizon for medical treatment of heart failure. J Cardiac Failure 1996; 2:S287-294.
13. Matsui S, Matsumori A, Matoba Y, Uchida A, Sasayama S. Treatment of virus-induced myocardial injury with a novel immunomodulating agent, vesnarinone. Suppression of natural killer cell activity and tumor necrosis factor-α production. J Clin Invest 1994; 94:1212-1217.
14. Shioi T, Matsumori A, Matsui S, Sasayama S. Inhibition of cytokine production by a new inotropic agent, vesnarinone, in human lymphocytes, T cell line, and monocytic cell line. Life Sci 1994; 54:PL11-16.
15. Sato Y, Matsumori A, Sasayama S. Inotropic agent vesnarinone inhibits cytokine production and E-selectin expression in human umbilical vein endothelial cells. J Mol Cell Cardiol 1995; 27:2265-2273.
16. Sasayama S, Matsumori A. Vesnarinone: a potent cytokine inhibitor. J Cardio Failure 1996; 2:251-258.
17. Kambayashi T, Mazurek N, Jacob CO, Wei N, Fong M, Strassmann G. Vesnarinone is a selective inhibitor of macrophage TNF release. Int J Immunopharmacol 1996; 18:371-378.
18. Jiang H, Biolekova B, Okazaki H, Clarence-Smith K, Johnson KP, Bergey G, et al. The effect of vesnarinone on TNFα production in human peripheral blood mononuclear cells and microglia; a preclinical study for the treatment of multiple sclerosis. J Neuroimmunol 1999; 97:134-145.
19. Matsumori A. The use of cytokine inhibitors: a new therapeutic insight into heart failure. Int J Cardiol 1997; 62:S3-12.
20. Hattori Y, So S, Hattori S, Kasai K, Shimoda S. Vesnarinone inhibits induction of nitric oxide synthase in J774 macrophages and rat cardiac myocytes in culture. Cardiovasc Res 1995; 30:187-192.
21. Matsumori A, Okada I, Shioi T, Fukukawa Y, Nakamura T, Ono K, et al. Inotropic agents differentially inhibit the induction of nitric oxide synthase by endotoxin in cultured macrophages. Life Sci 1996; 59:PL121-125.
22. Busch FW, Tillmann A, Becker EW, Owsianowski M, Berg PA. The inhibitory effects of a positive inotropic quinolinone derivative, 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2-(1H)-quinolinone (OPC-8212), on bone-marrow progenitor cells and peripheral lymphocytes. Eur J Clin Pharmacol 1992; 42:629-633.
23. Nabeshima R, Aizawa S, Nakano M, Toyama K, Sugimoto K, Kaidow A, et al. Effects of vesnarinone on the bone marrow stromal cell-dependent proliferation and differentiation of HL60 cells in vitro. Exp Hematol 1997; 25:509-515.
24. Lazarus DD, Kambayashi T, Yato-Kioka M, Baunmann H, Jacob CO, Strassmann G. Vesnainone inhibits immune-mediated but not fas (CD95) agonist-mediated hepatic injury. Int J Immunopharmacol 1997; 19:49-58.
25. Maruyama I, Maruyama Y, Nakajima T, Kitajima I, Osame M, Zhao JQ, et al. Vesnarinone inhibits production of HIV-1 in cultured cells. Biochem Biophys Res Commun 1993; 195:1264-1271.
26. Matsui S, Matsumori A, Sasayama S. Vesnarinone prolongs survival and reduces lethality in a murine model of lethal endotoxemia. Life Sci 1994; 55:1735-1741.
27. waf1, by treatment with 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2-(1H)-quinolinone (vesnarinone) in a human salivary cancer cell line with mutant p53 gene. Cancer Lett 1997; 112:181-189.
28. waf1 gene promoter via Sp1 sites in a human salivary gland cancer cell line. Br J Cancer 2002; 87:1042-1046.
29. waf1 gene by treatment with a differentiation inducing agent, Vesnarinone in a human salivary gland cancer cell line. J Exp Clin Cancer Res 2003; 22:421-424.
30. Yoneda K, Yamamoto T, Ueta E, Osaki T. Induction of cyclin-dependent kinase inhibitor p21 in vesnarinone-induced differentiation of squamous cell carcinoma cells. Cancer Lett 1998; 133:35-45.
31. Isaka K, Fujito A, Sagawa Y, Yudate T, Nishi H, Ito H, et al. Induction of apoptosis in human choriocarcinoma cell lines by treatment with 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2-(1H)-quinolinone (vesnarinone). Oncol Rep 2002; 9:1299-1305.
32. Yokozaki H, Ito R, Ono S, Hayashi K, Tahara E. Effect of 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2-(1H)-quinolinone (vesnarinone) on the growth of gastric cancer cell lines. Cancer Lett 1999; 140:121-128.
33. Fujita M, Tsuchida T, Higashino K. Effect of vesnarinone in combination with anti-cancer drugs on lung cancer cell lines. Anticancer Drugs 1999; 10:119-127.
34. Fujita M, Tsuchida T, Fujita T, Higashino K. Effects of quinolinone derivative, vesnarinone, in combination with irradiation on human lung cancer cell lines. Oncol Rep 1999; 6:353-357.
35. Kubo K, Matsuzaki Y, Kato A, Terai S, Okita K. Antitumor effect of vesnarinone on human hepatocellular carcinoma cell lines. Int J Oncol 1999; 14:41-46.
36. Sato M, Harada K, Bando T, Shirakami T, Nakashiro K, Yoshida H, et al. Characteristics of antitumor activity of 3,4-dihydro-8-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2-(1H)-quinolinone (vesnarinone) against a human adenoid squamous carcinoma-forming cell line grown in athymic nude mice. Cancer Lett 1995; 91:1-9.
37. 1 arrest and have an anti-tumour effect on human non-small cell lung carcinoma cells grown in nude mice. Br J Cancer 1999; 80:96-103.
38. Tanaka S, Kawai K, Nakai S, Adachi M, Hori T. Apoptosis-inducing activity and growth suppression by vesnarinone on human glioma transplanted in nude mice. Neurol Res 1999; 21:409-414.
39. Kawai K, Konishi Y, Izumi K, Sato M, Adachi M, Hozumi M. Enhancement of anticancer effects of radiation and conventional anticancer agents by a quinolinone derivative, vesnarinone: studies on human gastric cancer tissue xenografts in nude mice. Anticancer Res 1998; 18:405-412.
40. Nio Y, Ohmori H, Minari Y, Hirahara N, Sasaki S, Takamura M, et al. A quinolinone derivative, vesnarinone (OPC-8212), significantly inhibits the in vitro and in vivo growth of human pancreatic cancer cell lines. Anticancer Drugs 1997; 8:686-695.
41. Kondo T, Suzuki Y, Kitano T, Iwai K, Watanabe M, Umehara H, et al. Vesnarinone causes oxidative damage by inhibiting catalase function through ceramide action in myeloid cell apoptosis. Mol Pharmacol 2002; 61:620-627.
42. Fujiwara H, Arima N, Otsubo H, Matsushita K, Hidaka S, Arimura K, et al. Vesnarinone exhibits antitumor effect against myeloid leukemia cells via apoptosis. Exp Hematol 1997; 25:1180-1186.
43. Khalaf W, Maina C, Byers J, Harvey W. Interferon-α2b and vesnarinone influence levels of tumor necrosis factor-α, apoptosis, or interleukin 6 in ESKOL, a hairy cell leukemia cell line. A potential cytokine and oncogene relationship regulating apoptosis in suggested. Leuk Res 2002; 26:169-177.
44. Nara N, Kurokawa H, Tohda S, Tomiyama J, Nagata K, Tanikawa S. Effect of vesnarinone, a quinolinone derivative, on the growth of leukemic blasts in acute myelogenous leukemia. Exp Hematol 1997; 25:199-204.
45. Sato S, Tomoyasu S, Okabe-Kado J, Hozumi M, Tsuruoka N, Nakai S, et al. Induction of differentiation and enhancement of vincristine sensitivity of human erythroleukemia HEL cells by vesnarinone, a positive inotropic agent. Exp Hematol 1996; 24:37-42.
46. Uchida D, Kawamata H, Omotehara F, Miwa Y, Hino S, Begum NM, et al. Over-expression of TSC-22 (TGF-beta stimulated clone-22) markedly enhances 5-fluorouracil-induced apoptosis in a human salivary gland cancer cell line. Lab Invest 2000; 80:955-963.
47. Omotehara F, Uchida D, Hino S, Begum NM, Yoshida H, Sato M, et al. In vivo enhancement of chemosensitivity of human salivary gland cancer cells by overexpression of TGF-beta stimulated clone-22. Oncol Rep 2000; 7:737-740.
48. Hino S, Kawamata H, Uchida D, Omotehara F, Miwa Y, Begum NM, et al. Nuclear translocation of TSC-22 (TGF-beta-stimulated clone-22) concomitant with apeptosis: TSC-22 as a putative transcriptional regulator. Biochem Biophys Res Commun 2001; 278:659-664.
49. Hino S, Kawamata H, Omotehara F, Uchida D, Miwa Y, Begum NM, et al. Cytoplasmic TSC-22 (transforming growth factor-β-stimulated clone-22) markedly enhances the radiation sensitivity of salivary gland cancer cells. Biochem Biophys Res Commun 2002; 292:957-963.
50. Hino S, Kawamata H, Omotehara F, Uchida D, Begum NM, Yoshida H, et al. Leucine zipper structure of TSC-22 (TGF-β-stimulated clone-22) markedly inhibits the anchorage-independent growth of salivary gland cancer cells. Oncol Rep 2002; 9:371-374.
51. Uchida D, Omotehara F, Nakashiro K, Tateishi Y, Hino S, Begum NM, et al. Posttranscriptional regulation of TSC-22 (TGF-β-Stimulated Clone-22) gene by TGF-β1. Biochem Biophys Res Commun 2003; 305:846-854.
52. Shibanuma M, Kuroki T, Nose K. Isolation of a gene encoding a putative leucine zipper structure that is induced by transforming growth factor beta 1 and other growth factors. J Biol Chem 1992; 267:10219-10224.
53. Jay P, Ji JW, Marsollier C, Taviaux S, Berge-Lefranc J-L, Berta P. Cloning of the human homologue of the TGF beta-stimulated clone 22 gene. Biochem Biophys Res Commun 1996; 222:821-826.
54. Y antigen expression in treatment with differentiation inducing agent, vesnarinone, of a patient with salivary adenoid cystic carcinoma. Apoptosis 1997; 2:106-113.
55. Sato M, Harada K, Yura Y, Azuma M, Kawamata H, Iga H, et al. The treatment with differentiation- and apoptosis-inducing agent, vesnarinone, of a patient with oral squamous cell carcinoma. Apoptosis 1997; 2:313-318.
56. Patnaik A, Rowinsky EK, Tammara BK, Hidalgo M, Drengler RL, Garner AM, et al. Phase I and pharmacokinetic study of the differentiating agent vesnarinone in combination with gemcitabine in patients with advanced cancer. J Clin Oncol 2000; 18:3974-3985.